New shot could bring relief to teens with severe eczema

NCT ID NCT07042126

First seen Nov 18, 2025 · Last updated May 14, 2026 · Updated 28 times

Summary

This study tests a new medicine called 611 in Chinese teenagers (ages 12-17) with moderate-to-severe atopic dermatitis (eczema). The drug targets a protein involved in inflammation to reduce skin redness, itching, and rashes. About 180 participants will receive either 611 or a placebo, and doctors will check if their skin improves significantly after 16 weeks. The goal is to see if 611 can safely control eczema symptoms better than a dummy treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine

    RECRUITING

    Nanchang, Zhejiang, 310003, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100044, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Fourth Affiliated Hospital Zhejiang University School of Medicine

    RECRUITING

    Jinhua, Zhejiang, 322000, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.